An observational study in Cancer, sponsored by Verismo Therapeutics. Enrolling by invitation at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Verismo Therapeutics · Observational
The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.
This is a study for the Long Term Follow Up for all participants treated with Verismo Therapeutics' SynKIR CAR T cell products in accordance with regulatory guidance. The primary objective of this study is to monitor the long-term safety of SynKIR CAR T cell products.
No investigational product will be administered in this LTFU study. Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product under a Verismo Therapeutics parent protocol. Participants will be invited to enroll into this LTFU study after either early discontinuation from or completion of the parent protocol.
In accordance with regulatory guidelines, this study will follow participants for a period of 15 years following infusion of Verismo Therapeutics' SynKIR CAR T cell product, to monitor for delayed adverse events (AEs), detection of replication competent lentivirus (RCL), and to assess long-term efficacy and persistence of gene-modified T cells.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 60 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Verismo Therapeutics is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product in a Verismo Therapeutics parent protocol.
Participants are eligible to be included in the study only if all of the following criteria apply:
Exclusion Criteria:
There are no specific exclusion criteria.
Participants who previously received SynKIR-110 in an interventional trial
Drug: SynKIR-110
Participants who previously received SynKIR-310 in an interventional trial
Drug: SynKIR-310
Autologous T cells Transduced with Mesothelin KIR-CAR
Autologous T Cells transduced with CD19 KIR-CAR
To monitor the long-term safety of participants that have been infused with a SynKIR CAR T cell product
Frequency and severity of delayed AEs considered related to SynKIR CAR T cell product
Time frame: Up to 15 years from SynKIR CAR T cell product administration
To monitor the long-term safety of participants that have been infused with a SynKIR CAR cell product
Presence of RCL VSV-G DNA
Time frame: Up to 15 years from SynKIR CAR T cell product administration
To assess the long-term clinical efficacy of SynKIR CAR T cell product
Overall survival
Time frame: Up to 15 years from SynKIR CAR T cell product administration
To assess the long-term clinical efficacy of SynKIR CAR T cell product
Progression-free survival
Time frame: Up to 15 years from SynKIR CAR T cell product administration
To assess the persistence of SynKIR-modified T cells
Presence of a SynKIR CAR DNA sequence
Time frame: Up to 15 years from SynKIR CAR T cell product administration
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Verismo Therapeutics